期刊文献+

HPLC法检测人血浆中利奈唑胺浓度 被引量:3

Determination of linezolid in human plasma by HPLC
原文传递
导出
摘要 目的建立检测人血浆利奈唑胺的HPLC法。方法以Eclipse XDB-C_(18)为色谱柱;甲醇-水(45:55,V/V)为流动相,流速1.0mL·min^(-1);血浆样品经70%高氯酸沉淀后,在254nm波长下进行检测。结果利奈唑胺在质量浓度0.25~50mg·L^(-1)内线性关系良好(r=0.999 8),定量下限为0.25mg·L^(-1);低、中、高浓度的日间、日内精密度(RSD)均<10%,相对回收率分别为96.40%、103.24%、100.33%,提取回收率>75%。结论本方法操作简便,结果准确,适用于血浆中利奈唑胺浓度的检测。 AIM To establish a HPLC method for the determination of linezolid in human plasma.METHODS The analytical column was packed with Eclipse XDB-C_(18),the mobile phase was methanol-water(45:55,V/V),the flow rate was 1.0 mL·min^(-1),and the detection wavelength was 254 nm.Proteins in plasma samples were precipitated by 70%perchloric acid,and detected at 254 nm.RESULTS The liner range of linezolid in human plasma was 0.25-50 mg·L^(-1)(r =0.999 8).The limit of detection was 0.25 mg·L^(-1).The intra-day and inter-day RSD for assaying the plasma sample containing three concentration of linezolid were both lower than 10%.The relative recovery were 96.40%, 103.24%and 100.33%,respectively.The absolute recovery were more than 75%.CONCLUSION The HPLC method to determine linezolid in plasma is simple,high selectivity and sensitivity.
出处 《中国临床药学杂志》 CAS 2011年第2期105-108,共4页 Chinese Journal of Clinical Pharmacy
关键词 利奈唑胺 血药浓度 HPLC法 linezolid plasma drug concentration HPLC
  • 相关文献

参考文献8

  • 1Abena PA, Mathievx VG, Scheiff JM, et al. Linezolid and reversible myelosupp ression[J]. J Am Meal Assoc, 2001, 286(16): 1973.
  • 2Miehalska K, Pajchd G, Tyski S. l)etenninafion of linezolid and its impurities using sweeping preeo~centration by micellar capillary deetn~omsis[J]. J Pharm Biomed Anal, 2008, 48(2): 321.
  • 3Toutain J, Boselli E, Djabaroufi S, et al. Detmanination of linezolid in plasma and bronchoalveolar lavage by high-performance liquid ehrtmog- raphy with ultraviolet detection using a fully automated extraction method [J]. J Onmmtogr B Analyt Technol Biomed Life Sci, 2004, 813(1): 145.
  • 4Boak LM, Li J, Nation RL, et al. High-performance liquid chromato- gmc method for simple and rapid detenninatlon d linezolid in humanplasma[J]. Biomed Chogr, 2006, 20(8) : 782.
  • 5I.overing AM,Le FR, Hovsepian L, et el. Phanmcnetic evaluation d linezalid in patients with major thermal injuries [ J ]. J Anfimicvob Chemer, 2009, 63(3): 553.
  • 6Peng GW, Stryd RP, Murata S, et al. Determination d linezolid in plasma byvetsed-phase high-performance liquid dmmmtographyl[J]. JPhann Biomed Anal, 1999, 20(1):65.
  • 7董海燕,董亚琳,王雪,杨华,刘娟娟.HPLC法测定人血清中利奈唑胺浓度及其临床应用[J].药物分析杂志,2010,30(2):199-203. 被引量:22
  • 8Stalker DJ, Jungbluth GL. Clinical plaannaed6neties d line.lid, anovd oxazolidlnorm antibaetexial [ J ]. Clin Phammeoldnet, 2003, 42 ( 13 ) : 1129.

二级参考文献27

  • 1Abena PA, Mathieux VG, Scheiff JM, et al. Linezolid and reversible myelosuppression. J Am Med Assoc ,2001,286 : 1973.
  • 2Santos RP, Prestidge CB, Brown ME, et al. Pharmacokinetics and pharmacodynamics of linezolid in children with cystic fibrosis. Pul- mortology,2009,44(2) : 148.
  • 3Lovering AM, Le FR, Hovsepian L, et al. Pharmacokinetic evaluation of linezolid in patients with major thermal injuries. J Antimicrob Chemother,2009,63 ( 3 ) :553.
  • 4Brier ME, Stalker D J, Aronoff GR, et al. Pharmaeokineties of linezolid in subjects with renal dysfunction. Antimicrob Agents Chemother, 2003,47 (9) :2775.
  • 5Tsuji Y, Hiraki Y, Mizoguchi A ,et al. Pharmacokinetics of repeated dosing of linezolid in a hemodialysis patient with chronic renal failure. J Infect Chemother, 2008,14 ( 2 ) : 156.
  • 6Tsiodras S, Gold HS, Sakoulas G, et al. Linezolid resistance in a clinical isolate of staphylococcus aureus. Lancet ,2001,358:207.
  • 7Ruiz ME, Guerrero IC, Tuazon CU. Endocarditis caused by methicillin -resistant Staphylococcus aureus:treatment failure with linezolid. Clin Infect Dis ,2002,35:1018.
  • 8Gonzales RD, Schreckenberger PC, Graham MB,et al. Infections due to vancomycin - resistant enterococcus faecium resistant to linezolid. Lancet ,2001,357 : 1179.
  • 9Attassi K, Hershberger E, Alam R,et al. Thrombocytopenia associated with linezolid therapy. Clin Infect Dis ,2002,34:695.
  • 10MacGowan AP. Establishing MIC breakpoints and the interpretation of in vitro susceptibility tests. J Antimicrob Chemother, 2001,48 ( Suppl SI ) : 17.

共引文献21

同被引文献23

  • 1Phillips OA,Abdel-Hamid ME,al-Hassawi NA,et al.Determination of linezolid in human plasma by LC-MS-MS.Analyst,2001,126(5):609-14.
  • 2Santa RP,Prestidge CB,Brown ME,et al.Pharmacokinetics and Pharmacodynamics of Linezolid in Children With Cystic Fibrosis.Pulmonology,2009,44(2):149-54.
  • 3Lovering A M,Le FR,Hovsepian L,et al.Pharmacokinetic evaluation of linezolid in patients with major thermal injuries.J Antimicrob Chemother,2009,63(3):553-9.
  • 4Brier ME,Stalker DJ,Aronoff G,et al.Pharmacokinetics of Linezolid in Subjects with Renal Dysfunction.Antimicrob Agents Chemother,2003,47(9):2775-80.
  • 5PALADINO J A. Linezolid: An oxazolidinone antimicrobial agent. Am J Health Syst Pharm, 2002,59(24):2413-2425.
  • 6BOAK L M, LI J, NATION R L, et al. High-performance liquid chromatographic method for simple and rapid determination of linezolid in human plasma. Biomed Chrom, 2006,20(8):782-786.
  • 7TOBIN C M, SUNDERLAND J, WHITE L O, et al. A simple, isocratic high-performance liquid chromatography assay for linezolid in human serum.J Anti Chem, 2001,48(5):605-608.
  • 8ClOS A, KUS K, OLEKSIAK J S. Determination of linezolid in human serum by reversed-phase high-performance liquid chromatography with ultraviolet and diode array detection. Acta Poloniae Pharm Drug Res, 2013,70(4):631-641.
  • 9PENG G W, STRYD R P, MURATA S, et al. Determination of linezolid in plasma by reversed-phase high-performance liquid chromatography. J Pharm Biomed Anal, 1999,20(12):65-73.
  • 10Ament PW, Jamshed N, Home JP. Linezolid: its role in the treatment of gram-positive, drug-resistant bacterial infections[J]. Am Fam Physi-eian, 2002, 65(4): 663.

引证文献3

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部